Intra-Cellular Therapies Inc.
ITCI
ITCI was delisted on the 1st of April, 2025.
127 hedge funds and large institutions have $469M invested in Intra-Cellular Therapies Inc. in 2019 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 52 increasing their positions, 28 reducing their positions, and 13 closing their positions.
873% more call options, than puts
Call options by funds: $42.6M | Put options by funds: $4.38M
86% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 28
12% more capital invested
Capital invested by funds: $418M → $469M (+$51.5M)
0% more funds holding
Funds holding: 127 → 127 (0)
0% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TA
Teachers Advisors
New York
|
+$4.89M |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$4.82M |
| 3 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
+$3.7M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.61M |
| 5 |
Schroder Investment Management Group
London,
United Kingdom
|
+$2.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$12.2M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.84M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$2.85M |
| 4 |
Millennium Management
New York
|
-$2.72M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$2.04M |
ITCI Hedge Fund Activity: Q1 2019 in Review
127 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q1 2019, worth a combined $469M — up 12% from $418M a quarter earlier.
Fund positioning in ITCI was balanced in Q1 2019: 13 funds opened new positions, 13 closed out, 52 added to existing stakes and 28 trimmed.
The largest buyer was Teachers Advisors, adding an estimated $4.89M. The largest seller was Citadel Advisors, cutting an estimated $12.2M.
- 127 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q1 2019, unchanged from Q4 2018.
- Funds reported $469M of Intra-Cellular Therapies Inc. stock for Q1 2019, up 12% quarter-over-quarter.
- 13 funds opened new Intra-Cellular Therapies Inc. positions in Q1 2019 and 13 closed out, a net change of 0 holders.
- The largest Intra-Cellular Therapies Inc. buyer in Q1 2019 was Teachers Advisors, an estimated $4.89M added.
- The largest Intra-Cellular Therapies Inc. seller in Q1 2019 was Citadel Advisors, an estimated $12.2M sold.
Based on aggregated 13F filings for Q1 2019.